See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Republican Party
US Politics
Natural Disasters
Democratic Party
Donald Trump
Money
Senate
LGBTQ+
Drones
Education
Published • loading... • Updated

Merck, Daiichi Pull US Application for 'guided Missile' Therapy for Lung Cancer

Summary by Medscape
Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a...

2 Articles

All
Left
Center
Right
pharmaceutical-technology.compharmaceutical-technology.com

Daiichi and MSD withdraw US application for lung cancer treatment

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).

Read Full Article
MedscapeMedscape

Merck, Daiichi Pull US Application for 'guided Missile' Therapy for Lung Cancer

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a...

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Thursday, May 29, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Merck

Merck

Medical

Medical

United States

United States

News
For You
SearchBlindspotLocal